{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-277627","form_type":"8-K","ticker":"AVIR","cik":"0001593899","company_name":"Atea Pharmaceuticals, Inc.","filed_at":"2025-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.863384+00:00","generated_at":"2026-05-16T21:12:12.916645+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Atea Q3 net loss $42.0M ($0.53/share); HCV Phase 3 C-BEYOND fully enrolled by end-2025; HEV program launched","bullets":["Net loss of $42.0M ($0.53 diluted EPS) vs $31.2M ($0.37) in Q3 2024; R&D expenses rose to $38.3M.","Cash, equivalents and marketable securities $329.3M at Sep 30, 2025, down from $454.7M at Dec 31, 2024.","HCV Phase 3 C-BEYOND (US/Canada) enrollment on track for completion by end 2025; topline mid-2026.","New HEV development program with two lead candidates AT-587 and AT-2490; IND-enabling studies ongoing.","Completed $25M stock repurchase program: 7,673,793 shares at avg $3.26; shares outstanding 78,126,796."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-277627","json":"https://secwatch.observer/filing/0001193125-25-277627.json","markdown":"https://secwatch.observer/filing/0001193125-25-277627.md","text":"https://secwatch.observer/filing/0001193125-25-277627.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1593899/000119312525277627/0001193125-25-277627-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1593899/000119312525277627/d47505d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T21:12:12.916645+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}